beat driven impress growth soliri gmg conjunct rapid
convers ultomiri pnh ultomiri fda approv ahu well
expect convers among ahu patient progress compar rate
solid growth prospect hope continu execut improv investor
alexion revenu ep beat consensu alexion rais guidanc third
time year full recap earn see previou note clear alexion
franchis particular franchis continu perform well total revenu
y/i vs consensu driven sale growth
y/i y/i asia pacif y/i off-set modestli row y/i
alexion total franchis growth across indic pnh ahu gmg nmosd
strong y/i
soliri sale q/q y/i vs consensu grew line
volum y/i increas uptak gmg offset transfer
ultomiri note strongest growth gmg date fact
 neurolog patient soliri sept sept
y/i ultomiri revenu vs consensu q/q includ
eu octob pnh patient german
convert soliri ultomiri
y/i even kanuma y/i solid quarter new patient
identifi improv ex-u fund agreement
alexion rais guidanc total revenu previous
soliris/ultomiri revenu previous
metabol revenu previous non-gaap ep
previous guidanc assum continu growth gmg
ultomiri convers pnh ahu modest contribut soliri launch nmosd
strong strensiq growth alexion intend build pipelin anticip spend
dollar percentag sale increas go next year manag also
note sever expect headwind revenu growth includ price fx
adjust estim consist new total revenu
estim y/i vs prior y/i new non-gaap
ep estim y/i vs previou y/i
pleas see page report import disclosur
alexion new manag team restor investor confid underli demand trend
soliri remain solid launch gmg set eclips launch pnh
ahu expect fear competit soliri wain franchis transfer
ultomiri follow januari launch strensiq wit strong launch
appear destin blockbust statu asset plu minor contribut
kanuma allow compani post industry-lead financi view alexion
premier orphan diseas compani think favor financi outlook increas
confid growth durabl complement franchis posit share
re-rat alexion one larg cap biotech solid growth
prospect consid top larg cap pick maintain price target
 launch ultomiri ahu
danicopan ph ii data pnh
clinic suppli readi
use phase ii/iii program
drive franchis sale
strensiq kanuma lal-d
achiev
rest pipelin creat
franchis grow faster
project achiev revenue
soliri ultomiri sale fall short
commerci regulatori setback
strensiq ultomiri
dilut acquisit
soliri approv treatment paroxysm nocturn hemoglobinuria pnh
atyp hemolyt urem syndrom ahu gmg next-gen
ultomiri approv pnh ahu octob pnh autoimmun
disord mark red blood cell deplet believ affect estim
patient world-wide candid soliri given price
approxim estim ww peak annual sale
pnh ahu caus overactiv complement pathway often kidney
soliri shown improv multipl hallmark diseas believ
ahu market could compar size pnh market sever refractori
gener myasthenia gravi gmg patient think gmg potenti new
oppi beyond soliri strensiq kanuma achiev commerci success
respect peak sale
last week major pnh patient previous treat soliri
convert ultomiri thu month launch alexion
way toward achiev goal convert least market ultomiri
approxim eight month remain alexion need convert
addit pnh patient ultomiri monthli basi achiev convers
goal vs soliri patient transfer ultomiri monthli basi
first nine month launch alexion expect convers maintain momentum
month ahead broader prescrib base target -- follow implement
perman j-code octob expect remov barrier prescrib
said launch curv tend slow time alexion expect ultomiri
launch except inde updat metric announc morn suggest
convers rate begun slow soliri patient
transfer ultomiri past month
ex-u geographi ultomiri launch track ahead launch
germani patient convert ultomiri sinc drug enter
market juli place launch three month ahead launch time
point alexion note speed launch partli attribut concentr
treater base germani ultomiri also launch austria denmark finland
launch addit european countri anticip beyond though
ultomiri enter market japan last month launch also appear
track ahead launch time point
alexion continu aim best-in-class convers rate launch geographi
patient convert within first month launch
ultomiri approv adult children month age older atyp
hemolyt urem syndrom ahu octob alexion convers goal ahu
pnh -- ahu patient chronic soliri treatment
transit ultomiri within two year launch given silent natur diseas
subset ahu patient treat short cours soliri associ tma
event alexion believ potenti improv persist complianc
ultomiri particularli given increas risk tma event patient stop treatment
ultomiri conveni dose week howev soliri may remain
treatment choic patient continu prefer short cours treatment
acut set alexion work help ahu patient interest ultomiri
initi treatment present acut addit facilit convers
soliris-tr patient ultomiri transit out-pati follow care
expect uptak among ahu patient interest chronic treatment rapid
given rapid convers pnh steeper price discount ultomiri
ahu year mainten shorter durat treatment/
higher patient turnov ahu
year launch soliri gmg uptak show sign slow alexion
report strongest quarter date gmg growth meanwhil soliri
approv nmosd patient june ad second neurolog indic
metric soliri uptak among patient gmg nmosd provid
togeth alexion disclos neurolog patient soliri septemb
impli rate patient start treatment increas significantli
month previous alongsid launch soliri nmosd
earn call manag note gmg launch still lead edg
sign slow alexion continu believ approxim sever
refractori achr gmg patient suggest soliri penetr small
fraction address market
earlier month alexion announc agreement acquir achillion development-
stage compani develop oral factor inhibitor treatment diseas mediat
altern pathway complement system lead candid danicopan
phase ii develop pnh combin alexion soliri data
anticip phase ii proof-of-concept studi danicopan glomerulopathi
expect complet behind danicopan achillion develop second-
gener product phase data healthi volunt suggest
achiev complet sustain inhibit altern pathway phase
ii studi pnh plan initi
factor rate-limit enzym altern pathway fairli low plasma
concentr ug/ml importantli select inhibit altern pathway
leav lectin classic pathway intact -- may decreas infecti risk
associ inhibit factor also target small molecul
inhibitor oral bioavail wherea competitor therapi target complement
pathway requir iv subq deliveri thu factor inhibit potenti treat
alexion also reach agreement stealth biotherapeut option co-
develop commerci elamipretid mitochondri diseas option may
exercis follow phase result primari mitochondri myopathi pmm
expect pmm genet mitochondri diseas result cardiolipin
peroxid diseas character skelet muscl weak chronic fatigu
approv treatment elamipretid daili subq small molecul
bind stabil cardiolipin therebi improv mitochondri function alexion
choos exercis option follow phase data read-out compani
also gain right develop elamipretid barth syndrom leber hereditari optic
neuropathi geographi atrophi
septemb alexion announc licens agreement develop commerci eido
transthyretin amyloidosi attr stabil therapi japan phase studi
attr cardiomyopathi underway europ phase trial
attr polyneuropathi plan later year morn alexion announc plan
initi phase trial japan earli pend regulatori discuss
encourag alexion earn think result highlight
opportun growth remain front provid reason optim
franchis defens investor appreci despit
market gmg two year soliri best quarter growth indic yet
increas confid size opportun franchis
neurolog indic driver healthi growth next sever
year ultomiri also continu impress germani japan
strong patient physician interest ultomiri lead rapid convers think
bode well ultomiri launch across futur geographi indic suggest
unlik patient want switch back biosimilar avail
continu believ base ultomiri improv potenc conveni
well somewhat lower annual price rais bar competit
franchis think franchis suscept competit
market current assum though progress reward thu far
hope continu execut soliri neurolog launch increas confid
compani abil convert intern patient ultomiri could posit
share re-rat investor better appreci durabl potenti growth
complement franchis maintain price target
soliri eculizumab human monoclon antibodi approv
treatment paroxysm nocturn hemoglobinuria pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi
gmg soliri becom one success ultra-orphan drug
sale y/i soliri label expand includ
neuromyel optica nmo end june next-gener
complement inhibitor ultomiri seek advanc upon soliriss profil
offer greater conveni potenc phase studi use dose
paradigm demonstr non-inferior soliri trend
superior fda approv pnh grant end decemb
alexion plan convert least pnh market ultomiri
fda approv ahu grant octob alexion
expect convert least market ultomiri within two
year launch subq formul employ dose
on-going initi data anticip alexion also studi
subq co-administ halozym call
could extend dose interv given
steadi new patient add ultomiri abil protect franchis
competit estim sale alexion complement franchis
includ pnh ahu gmg alexion
market two addit ultra-orphan drug strensiq asfotas alfa
hypophosphatasia sever bone diseas approv
europ japan gener sale believ drug
potenti kanuma enzym replac therapi
lal defici unfortun alexion face challeng identifi lal-
patient peak sale like modest model
sale recent alexion acquir number earli stage asset build
pipelin alexion acquir wilson therapeut april gain
access treatment wilson diseas current phase
develop addit alexion obtain
acquisit syntimmun alexion aim advanc
pivot develop warm autoimmun hemolyt anemia waiha gmg
view alexion premier orphan diseas compani think
favor financi outlook increas confid compani abil
convert patient ultomiri posit share re-rat investor gain
confid growth durabl complement franchis
alexion one larg cap biotech solid growth prospect
consid top larg cap pick maintain price target
cowen compani
reportedcowen estimatesoliri percent percent percent cowen
result phase ii danicopan combin soliri pnh
potenti competitor apelli releas result ph trial pnh
potenti regulatori approv soliri nmosd eu japan
initi phase ultomiri iv nmosd potenti bridg subq
initi poc studi ultomiri iv al
data pk-base registr phase bridg studi weekli subq
initi phase ultomiri iv hsct-tma
launch pnh addit eu geographi
potenti approv ultomiri subq pnh ahu
complet phase enrol wilson diseas
clinic suppli readi use phase i/ii program
initi phase ii/iii trial waiha
initi phase trial subq formul healthi volunt
initi phase ii/iii trial subq formul gmg
cowen compani
cowen compani
franchis y/i y/i y/i y/i y/i growthstrensiq sale y/i y/i y/i gross total product oper oper oper incom non- tax incom loss net incom y/i base compens incom includ stock includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep cowen
cowen compani
franchis sale kanuma sale y/i gross total gener product oper incom tax net y/i includ stock comp ep exclud stock comp expens non-cash tax amort acquir intang cost associ acquisit ep annual model cowen
cowen compani
oper activitiesnet incom net use oper activitiesnon-cash exit currency/hedg compens conting gain loss forward asset liabilitiesaccount expens payable/accru revenuetot use oper invest activitieschang market securitiespay acquisitionspurchas invest financ activitiesdebt issuanc cost excess tax benefit stock option payment mortagag note loan stock salenet proce issuanc common stock financ fx chang cash equival begin cash equival end summari oper itemsbegin exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
great major alexion valu deriv singl product soliri risk
expect soliri includ potenti slowdown pnh market unknown
size ahu market regulatori clinic develop risk indic
includ nmo mg alexion share could also wit meaning downsid
meet failur
